High-dose sequential chemotherapy and rituximab (R-HDS) supported by autologous stem cell transplantation (ASCT) in patients (pts) with systemic B-cell lymphoma with CNS involvement (SCNSL) at diagnosis or relapse: Interim analysis of feasibility and activity of a phase II trial.

医学 美罗华 内科学 阿糖胞苷 自体干细胞移植 胃肠病学 中性粒细胞减少症 依托泊苷 环磷酰胺 噻替帕 化疗 肿瘤科 移植 外科 淋巴瘤
作者
Andrea Assanelli,K. Patti,S Cortelazzo,Luigi Rigacci,Liliana Devizzi,Marco Foppoli,Antonino Mulè,Fabio Ciceri,Corrado Tarella,Andrés J.M. Ferreri
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:28 (15_suppl): 8081-8081 被引量:1
标识
DOI:10.1200/jco.2010.28.15_suppl.8081
摘要

8081 Background: High-dose (HD) chemotherapy supported by ASCT exhibited promising results in a few, small retrospective series of SCNSL. Herein we report the interim analysis of a phase II trial (ClinicalTrials.gov #NCT00801216) addressing a new R-HDS combination with ASCT in these poor-prognosis pts. Methods: Pts (≤65 ys old; ECOG PS 0-3) with SCNSL at diagnosis or relapse were treated with 2 c. of HD-methotrexate + HD-cytarabine (induction); 3 sequential c. of HD-cyclophosphamide, HD-cytarabine, HD-etoposide (R-HDS); BCNU-thiotepa-based conditioning and ASCT. Pts received 6 doses of i.v. rituximab and 4 doses of intrathecal liposomal cytarabine. Pts with CNS residual disease were referred to RT. The 2-year EFS is the primary endpoint (P0 40%; P1 60%; 38 pts required). This approach will be considered active if ≥21 pts will be progression free at 2 yrs. Results: the first 13 registered pts (median age 52 ys, 31-65; M/F ratio 1.6) were analyzed. Six pts were treated at diagnosis; 8 had systemic disease; no pt had positive CSF. Histotypes were diffuse large B-cell (10), mantle cell (2) and follicular (1) lymphomas. Bulky disease (1), ECOG-PS 2-3 (4) and B-symptoms (1) were uncommon; elevated LDH levels were observed in 10 pts. Treatment was completed in 8 pts, is ongoing in 3 (R-HDS), and was interrupted in 2: before conditioning in a poor mobilizer and after the first course due to PD. There were no toxic deaths. G4 neutropenia and thrombocytopenia were reported in all pts, febrile neutropenia in 7, other septic complications in 5. G3-4 non-hematological toxicity was not reported. PBSC collection was successful in 8 of the 9 referred pts (median 9.35 × 109/kg). Nine (69%) pts achieved a CR, 3 a PR (ORR 92%), 1 pt had PD. No pt received RT. At a median f-up of 15 m, 4 pts experienced relapse/PD (CNS 3, extra-CNS 1), with a 2-yr EFS of 46%; 9 pts are alive with a 2-yr OS of 54%. Conclusions: R-HDS supported by ASCT is feasible in pts ≤65 ys old with SCNSL. Preliminary results with this intensive approach are encouraging in this condition, with otherwise dismal prognosis. No significant financial relationships to disclose.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
西北望发布了新的文献求助10
1秒前
waayu完成签到 ,获得积分10
1秒前
小武丁发布了新的文献求助10
2秒前
2秒前
FashionBoy应助LLB采纳,获得10
2秒前
2秒前
2秒前
3秒前
隐形曼青应助柚子采纳,获得10
3秒前
逃跑计划完成签到,获得积分10
5秒前
务实幻露完成签到,获得积分10
5秒前
6秒前
西北望完成签到,获得积分10
6秒前
7秒前
zhang值发布了新的文献求助10
7秒前
8秒前
丘比特应助自觉平露采纳,获得10
8秒前
lqiqivv发布了新的文献求助10
8秒前
10秒前
奔跑石小猛完成签到,获得积分10
10秒前
11秒前
11秒前
hhhheyyyyo完成签到,获得积分10
11秒前
细腻天蓝完成签到 ,获得积分10
12秒前
12秒前
ambitiouslu发布了新的文献求助10
13秒前
13秒前
nykal发布了新的文献求助10
13秒前
朴实浩宇完成签到,获得积分10
14秒前
十点十分发布了新的文献求助10
14秒前
南信第一深情完成签到,获得积分10
14秒前
北落完成签到 ,获得积分20
15秒前
吃肯德基发布了新的文献求助30
15秒前
16秒前
16秒前
piaoyingzhiyu发布了新的文献求助10
17秒前
17秒前
所所应助科研通管家采纳,获得10
17秒前
ding应助科研通管家采纳,获得10
17秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
England and the Discovery of America, 1481-1620 600
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3572795
求助须知:如何正确求助?哪些是违规求助? 3142958
关于积分的说明 9449441
捐赠科研通 2844307
什么是DOI,文献DOI怎么找? 1563431
邀请新用户注册赠送积分活动 731771
科研通“疑难数据库(出版商)”最低求助积分说明 718695